Fuertes, Baby Boy .

HRN: 22-13-86  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/27/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/27/2022
11/02/2022
IVT
50mg
OD
Maternal Factor: (+) RAgT; Thinly MSAF
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Bloodstream    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: